Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals director Paul A. Friedman reported insider transactions in company common stock. On January 9, 2026, he exercised a fully vested stock option for 24,520 shares of common stock at an exercise price of $15.8 per share and then sold multiple small blocks of common stock the same day under a Rule 10b5-1 trading plan adopted on September 10, 2025. The reported sale prices are disclosed as weighted averages, with underlying trades occurring at prices generally ranging from about $511.71 to $545.79 per share. After these transactions, he directly held 187,164 shares of common stock and 280 stock options, and also reported 655,540 shares held indirectly through SQN LLC, for which he and his spouse are managing members.
Madrigal Pharmaceuticals director Rebecca Taub reported stock transactions dated 01/09/2026. She exercised a stock option for 240 shares of common stock at $15.80 per share and then sold 40 shares at $545.79 and 200 shares at a weighted average price of $551.242. These sales were made under a Rule 10b5-1 trading plan adopted on September 10, 2025. After the reported sales, she directly owned 455,589 shares of common stock. The filing also lists 655,540 shares held indirectly by SQN, LLC, an entity for which she and her spouse are managing members, and she disclaims beneficial ownership of those securities except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals director Rebecca Taub reported an insider transaction involving stock options and common shares of Madrigal Pharmaceuticals, Inc. (MDGL) dated 01/09/2026. She exercised a stock option for 18,410 shares of common stock at an exercise price of $15.8 per share and acquired the same number of common shares.
On the same date, she then sold Madrigal common stock in numerous open-market transactions under a Rule 10b5-1 trading plan, at weighted-average prices disclosed in ranges from $511.71 to $539.44 per share. After these trades, she held 455,589 shares of common stock directly and 655,540 shares indirectly through SQN, LLC, where she and her spouse are managing members, while disclaiming beneficial ownership beyond any pecuniary interest.
MDGL filed a Rule 144 notice covering the planned sale of 18650 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ.
These shares were acquired on 01/09/2026 by exercising stock options for cash and have an aggregate market value of 10373503.00. The issuer reports 22711420 shares outstanding. In the past three months, 10b5-1 sales disclosed include 18650 shares for Rebecca A Taub with gross proceeds of 10297573.26 and 24800 shares for Paul A Friedman with gross proceeds of 13694158.24.
Madrigal Pharmaceuticals disclosed an insider transaction by a company director on December 10, 2025. The director acquired 24,800 shares of common stock at $15.8 per share and, on the same day, sold 24,800 shares in multiple open-market trades at weighted average prices described in several ranges between approximately $547 and $555, all under a Rule 10b5-1 trading plan adopted on September 10, 2025.
After these transactions, the director beneficially owned 187,164 shares directly and 655,540 shares indirectly through SQN LLC, where the director and spouse are managing members and disclaim beneficial ownership beyond any pecuniary interest.
Madrigal Pharmaceuticals director reported several stock transactions dated 12/10/2025. The reporting person exercised a stock option to acquire 18,650 shares of common stock at $15.8 per share, then sold multiple blocks of shares the same day under a Rule 10b5-1 trading plan adopted on September 10, 2025 at weighted-average prices reported between $547.16 and $555.31 per share, plus an additional sale at $555.39 per share.
The reporting person also made a charitable contribution of 5,455 shares of common stock to a donor advised fund. After these transactions, they held 455,589 shares directly and 655,540 shares indirectly through SQN LLC, where the reporting person and a spouse are managing members, with beneficial ownership of those indirect shares disclaimed except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals (MDGL) reported that its Chief Commercial Officer filed a Form 4 disclosing multiple sales of common stock on 11/21/2025. One sale of 894 shares was made by the company on the officer’s behalf to cover tax withholding tied to vesting of restricted stock units and was automatic, not at the officer’s discretion. Additional market sales were executed the same day in small blocks under a Rule 10b5-1 trading plan adopted on November 5, 2024, at weighted average prices generally between about $547 and $565 per share. Following these transactions, the officer directly beneficially owned 10,032 shares of Madrigal common stock.
Madrigal Pharmaceuticals (MDGL) reported insider activity by a director on 11/13/2025. The filing shows two option exercises and subsequent open‑market sales executed under a Rule 10b5‑1 trading plan adopted on August 14, 2025.
The director exercised stock options for 2,500 shares at an exercise price of $7.36 and 6,000 shares at $16.46. Following the exercises, multiple sales occurred the same day across several tranches at weighted average prices, with disclosed ranges from $514.03 to $528.94 per share. After these transactions, the filing lists 21,197 shares of common stock beneficially owned on a direct basis.
The option entries indicate the underlying shares were fully vested and exercisable. Price footnotes state each reported sale price is a weighted average, with full trade‑level details available upon request.
Madrigal Pharmaceuticals (MDGL) director reported option exercises and share sales. On 11/05/2025, the insider exercised stock options for 5,470 shares at $9.45, 10,000 shares at $303.79, and 1,105 shares at $280.04 (all fully vested). The insider then sold multiple blocks of common stock, with weighted-average sale prices ranging from about $480.2397 to $490.9817, as detailed in footnotes. After these transactions, the insider directly beneficially owned 2,627 shares.
Madrigal Pharmaceuticals (MDGL) reported a sharp commercial ramp for Rezdiffra as product revenue reached $287.3 million in Q3 2025, up from $62.2 million a year ago. For the nine months ended September 30, 2025, product revenue totaled $637.3 million versus $76.8 million in 2024.
The company posted a net loss of $114.2 million for Q3 and $229.7 million year-to-date, reflecting higher selling, general and administrative expenses tied to commercialization and increased R&D. Liquidity remained strong with cash, cash equivalents and marketable securities of $1.11 billion, while long‑term debt rose after funding a $350.0 million initial term loan under a new credit facility that provides up to $500.0 million in commitments and requires at least $100.0 million of unrestricted cash. Accrued liabilities include a $117.3 million CSPC license upfront expense accrued and paid in October.
Rezdiffra received European Commission approval in August 2025 and launched in Germany in September, adding an early ex‑U.S. foothold alongside U.S. sales.